Business
AGM Correction
AGM Correction.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n\n \n13 May 2025\n \nHemogenyx Pharmaceuticals plc\n \n(\"Hemogenyx Pharmaceuticals\" or the \"Company\")\n \nAGM Correction\nHemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it is writing to Shareholders to explain that the Company's recent Notice of Annual General Meeting (the \"Notice\") contained a manifest clerical error.\nThis clerical error relates only to Resolutions 6 and 7, which, in the case of Resolution 6, concerns the authority sought by the Directors to allot shares in the Company and, in the case of Resolution 7, the disapplication of pre-emption rights.\nThe resolutions as printed in the Notice include a quite obviously incorrect number for the nominal value of the shares to which the proposed authorities would apply (the number mistakenly used was the number of shares in issue rather than their nominal value). Shareholders will note that the description of the authorities sought \"….(representing approximately 100% of the nominal value of the issued ordinary share capital of the Company)….\" is quite obviously correct in the context.\nThis is purely an administrative oversight, and the intention was always for the authorities to be limited to the 100% of the Company's issued share capital as described. Directors apologise for any confusion this may have caused notwithstanding the intention of the extent of the authorities sought being clear from the description in each of the resolutions themselves.\nAccordingly, the corrected resolutions, which will be presented at the Company's AGM, are as follows:\nCorrected Resolution 6:\nDirectors' authority to allot shares\nTHAT, in accordance with section 551 of the Companies Act 2006 (\"CA 2006\"), the Directors be generally and unconditionally authorised to allot shares in the Company and to grant rights to subscribe for, or to convert any security into, shares in the Company (the \"Rights\") up to an aggregate nominal amount of £40,935.39 (representing approximately 100% of the nominal value of the issued ordinary share capital of the Company) provided that this authority shall, unless renewed, varied or revoked by the Company, expire on the commencement of the next Annual General Meeting of the Company or 29 August 2026, whichever is earlier to occur, save that the Company may, before such expiry, make offer(s) or enter...